Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/116223
Title: | ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD |
Author: | Watz, Henrik Troosters, Thierry Beeh, Kai M. García Aymerich, Judith Paggiaro, Pierluigi Molins, Eduard Notari, Massimo Zapata, Antonio Jarreta, Diana Garcia Gil, Esther |
Keywords: | Malalties pulmonars obstructives cròniques Condició física Chronic obstructive pulmonary diseases Physical fitness |
Issue Date: | 24-Aug-2017 |
Publisher: | Dove Press |
Abstract: | The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of aclidinium/formoterol (AB/FF) 400/12 mug twice daily on lung hyperinflation, exercise capacity, and physical activity in patients with moderate-to-severe COPD. Patients received AB/FF (n=134) or placebo (n=133) (1:1) via the Genuair/Pressair(R) dry powder inhaler for 8 weeks. From Weeks 5 to 8, all patients participated in behavioral intervention (BI; daily messages providing step goals). The primary end point was trough functional residual capacity (FRC) at Week 4. Exercise endurance time and physical activity were assessed at Week 4 (pharmacotherapy only) and at Week 8 (8 weeks of pharmacotherapy plus 4 weeks of BI). Other end points included post-dose FRC, residual volume, and inspiratory capacity (IC) at rest and during exercise. After 4 weeks, trough FRC improved with AB/FF versus placebo but did not reach significance (125 mL; P=0.0690). However, post-dose FRC, residual volume, and IC at rest improved significantly with AB/FF at Week 4 versus placebo (all P<0.0001). AB/FF significantly improved exercise endurance time and IC at isotime versus placebo at Week 4 (P<0.01 and P<0.0001, respectively) and Week 8 (P<0.05 and P<0.0001, respectively). AB/FF achieved higher step counts (P<0.01) with fewer inactive patients (P<0.0001) at Week 4 versus placebo. Following BI, AB/FF maintained improvements in physical activity at Week 8 and nonsignificant improvements were observed with placebo. AB/FF 400/12 mug demonstrated improvements in lung hyperinflation, exercise capacity, and physical activity versus placebo that were maintained following the addition of BI. A 4-week period of BI might be too short to augment the improvements of physical activity observed with AB/FF. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.2147/COPD.S143488 |
It is part of: | International Journal of Chronic Obstructive Pulmonary Disease, 2017, vol. 12, num. , p. 2545-2558 |
URI: | http://hdl.handle.net/2445/116223 |
Related resource: | http://dx.doi.org/10.2147/COPD.S143488 |
ISSN: | 1176-9106 |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
watz2017_2685.pdf | 2.44 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License